Tenaya Therapeutics Presents Late-Breaking Gene Therapy Data for ARVC at ASGCT 2026
Event summary
- Tenaya Therapeutics will present late-breaking oral data from the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy for PKP2-associated ARVC at ASGCT 2026 on May 15, 2026.
- The presentation includes one-year Cohort 1 results and early Cohort 2 data from the 3E13 vg/kg and 6E13 vg/kg dose levels.
- Two additional posters will detail patient advocacy research and TN-501 gene editing therapy development for PLN-R14del cardiomyopathy.
The big picture
Tenaya Therapeutics' presentation at ASGCT 2026 highlights the growing momentum in gene therapy for rare cardiovascular diseases. The focus on PKP2-associated ARVC, a condition with limited treatment options, underscores the strategic shift toward addressing genetic root causes of heart disease. With multiple abstracts accepted, Tenaya is positioning itself as a leader in cardiac gene editing and therapy.
What we're watching
- Clinical Efficacy
- How the one-year Cohort 1 results and early Cohort 2 data will impact TN-401's path to potential approval.
- Dose Optimization
- Whether the safety and efficacy profiles at different dose levels (3E13 vg/kg vs. 6E13 vg/kg) will guide future trial designs.
- Pipeline Progress
- The pace at which Tenaya can advance its early-stage pipeline, including TN-501 for PLN-R14del cardiomyopathy.
Related topics